Patrick W. Vincent

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text

Mutant Braf, Raf/mek/erk Pathway, Medicine +12

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <i>EGFR</i> and <i>ERBB2</i> Mutations that Are Resistant to Gefitinib

Jeffrey A. Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale et al. · Cancer Research · 2007 · 713 citations · Full text

Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor:  4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-<i>d</i>]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions

Jeff B. Smaill, Gordon W. Rewcastle, Joseph A. Loo et al. · Journal of Medicinal Chemistry · 2000 · 263 citations · Full text

Combinatorial Chemistry, Organic Chemistry, Pharmacotherapy +21

Induced Pluripotent Stem Cell Lines Derived from Equine Fibroblasts

Kristina Vintersten Nagy, Hoon‐Ki Sung, Puzheng Zhang et al. · Stem Cell Reviews and Reports · 2011 · 246 citations · Full text

Regenerative Medicine, Embryonic Stem Cell, Induced Pluripotent Stem Cell +14

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

Andrea J. Gonzales, Kenneth E. Hook, Irene W. Althaus et al. · Molecular Cancer Therapeutics · 2008 · 220 citations · Full text